Omeros Co. (NASDAQ:OMER – Get Rating) – Equities researchers at Cantor Fitzgerald issued their FY2023 earnings estimates for Omeros in a research note issued to investors on Wednesday, March 15th. Cantor Fitzgerald analyst B. Folkes expects that the biopharmaceutical company will earn ($2.61) per share for the year. The consensus estimate for Omeros’ current full-year earnings is ($2.31) per share.
Several other research analysts have also recently weighed in on OMER. StockNews.com started coverage on shares of Omeros in a research report on Thursday. They issued a “sell” rating on the stock. UBS Group cut shares of Omeros from a “buy” rating to a “neutral” rating in a research report on Thursday, December 8th.
Omeros Stock Down 9.9 %
Institutional Trading of Omeros
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Ronald Blue Trust Inc. purchased a new stake in shares of Omeros during the second quarter valued at approximately $30,000. Lesa Sroufe & Co bought a new position in shares of Omeros during the third quarter valued at $56,000. Coldstream Capital Management Inc. bought a new position in shares of Omeros during the fourth quarter valued at $40,000. Laurion Capital Management LP bought a new stake in Omeros in the 2nd quarter worth about $49,000. Finally, MetLife Investment Management LLC increased its holdings in Omeros by 139.3% in the 1st quarter. MetLife Investment Management LLC now owns 28,967 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 16,862 shares in the last quarter. Hedge funds and other institutional investors own 32.64% of the company’s stock.
Omeros Company Profile
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
- Get a free copy of the StockNews.com research report on Omeros (OMER)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.